Anthrogen CEO Kim Mi-hyung: "Beyond pain relief, we saw potential for cartilage regeneration with an injection"
Predicted impact: Low
CEO interview on cartilage regeneration potential; vague, no financial size or regulatory milestone disclosed.
Anterogen안트로젠
065660 · KOSDAQ · ₩065660 · 안트로젠
₩14,310▲ ₩490 (3.55%)End-of-day · Oct 26, 2026 · End-of-day prices.
Price · 1Y −38.85%
- Market cap
- ₩143B
- Enterprise value
- ₩101B
- P/E
- —
- P/B
- 1.8×
- Dividend yield
- 0.0%
- ROE
- −1.8%
- Net margin
- −17.1%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−76.8% from the high
₩13,390Today: ₩13,690 – ₩15,000₩61,800
Returns
- 1W−0.1%
- 1M−2.7%
- 3M−11.9%
- 6M−61.5%
- YTD−69.5%
- 1Y−38.3%
- Volume today
- 23,211
- 1.1× the 20-day average
- Traded today
- ₩329M
- Listed shares
- 10,006,100
- EPS (12 months)
- −₩143
- Earnings yield −1.0%
AI researchResearch being writtenOur AI is writing a report on this company from filed data, prices and news. Check back soon.
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 44 of 100 (50 is a normal day for this stock).
- SentimentMixedNews: The only filing is a general notice of a management matter with no detail on its impact. Community: 0 bullish, 0 bearish posts this week.
- MomentumFlat-1.8% over the last month; the price is below its 20-day average.
- News impactLow2 news items and filings in two weeks; 0 rated high impact, 0 medium.
Signals describe activity, not recommendations. Not financial advice.
Anterogen stock overview
Anterogen (안트로젠, KRX: 065660) is listed on KOSDAQ, in the Retail & Trade sector. The company is a biotech firm that develops and manufactures stem cell-based therapies, using bone marrow- and adipose-derived stem cells. Its shares closed at ₩14,310 on Oct 26, 2026, up 3.55% on the day, giving it a market value of ₩143B.
Key facts
- Market cap
- ₩143B
- Sector
- Retail & Trade
- Latest price change
- +3.55%
- As of
- Oct 26, 2026
- Main business
- The company is a biotech firm that develops and manufactures stem cell-based therapies, using bone marrow- and adipose-derived stem cells.
Quick answers about Anterogen
- What does Anterogen do?
- The company is a biotech firm that develops and manufactures stem cell-based therapies, using bone marrow- and adipose-derived stem cells. It commercialized Cupistem, a Crohn's fistula treatment described as the world's first adipose-derived stem cell therapy, in 2012, and is expanding its pipeline into tissue engineering-based therapies and rare or intractable diseases. It also holds the domestic marketing authorization and exclusive sales rights for the pulmonary hypertension drugs Remodulin and Tyvaso in Korea.
- What is the market cap of Anterogen?
- The market capitalisation of Anterogen was ₩143B at the close on Oct 26, 2026.
- Who are the largest shareholders of Anterogen?
- According to the latest official filings, the largest reported holders are Lee Seong-gu (14.72%, as of Jul 10, 2026); EMTEK (7.25%, as of Apr 21, 2026); Kim Mi-hyung (0.93%, as of Jul 9, 2026).
- When is the next earnings report from Anterogen?
- Korean companies rarely announce results dates in advance. Based on when Anterogen filed the same report in past years, its next 3q results is expected between Nov 13, 2026 and Nov 14, 2026.
- Does the National Pension Service own Anterogen?
- Yes. The National Pension Service held 0.30% of Anterogen shares as of Dec 31, 2019.
Company profile
The company is a biotech firm that develops and manufactures stem cell-based therapies, using bone marrow- and adipose-derived stem cells. It commercialized Cupistem, a Crohn's fistula treatment described as the world's first adipose-derived stem cell therapy, in 2012, and is expanding its pipeline into tissue engineering-based therapies and rare or intractable diseases. It also holds the domestic marketing authorization and exclusive sales rights for the pulmonary hypertension drugs Remodulin and Tyvaso in Korea.
Written by AI from the company's latest annual report.
- Korean name
- 안트로젠
- Sector
- Retail & Trade
- Themes
- Biotech (new drugs)
- CEO
- 이성구, 김미형(각자대표)
- Founded
- Mar 2000
- Listed
- Feb 2016
- Listed shares
- 10,006,100
- Fiscal year ends
- Month 12
- Website
- www.anterogen.com
Similar companies
- Samsung C&T028260 · ₩47T₩292,000+1.39%
- POSCO International047050 · ₩8.7T₩49,550−3.79%
- Youngone111770 · ₩3T₩67,400−2.32%
- ISC095340 · ₩3T₩140,600−5.19%
- Dong SUH Companies026960 · ₩2.7T₩27,300−1.44%
- SK Gas018670 · ₩2.3T₩251,000−3.09%
- Shinsegae004170 · ₩2.3T₩245,000−3.92%
- Lotte Shopping023530 · ₩2.3T₩81,400−2.63%
Recent news
Recent filings
See all- Major management matter relevant to investorsOct 26, 2026
- Major management matter relevant to investorsSep 17, 2026
- Half-year report (Jun 2026)Aug 14, 2026
- Major management matter relevant to investorsAug 4, 2026
- 5%+ holding reportJul 10, 2026
Titles in Korean until English translations are added.
Also known as: Anterogen / 안트로젠 / 065660 / KRX:065660
Source: KRX statistical information